Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Patent
1997-02-13
2000-10-17
Spear, James M.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
424465, 424468, 424470, A61K 922, A61K 946
Patent
active
061327700
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/SE96/01738 filed Dec. 20, 1996.
FIELD OF THE INVENTION
The present invention is related to new pharmaceutical preparations in the form of a tableted multiple unit effervescent dosage form comprising an active substance in the form of an acid susceptible proton pump inhibitor, i.e. acid labile H.sup.+ K.sup.+ ATPase inhibitors. The novel tableted dosage form is intended for oral use. Furthermore, the present invention refers to a method for the manufacture of such preparations and, to the use of such preparations in medicine.
BACKGROUND OF THE INVENTION
Acid labile H.sup.+ K.sup.+ ATPase inhibitors also named as proton pump inhibitors are for instance compounds known under the generic names omeprazole, lansoprazole, pantoprazole, pariprazole, leminoprazole and others.
These active substances are useful for inhibiting gastric acid secretion in mammals and especially in man. In a more general sense, they may be used for prevention and treatment of gastric-acid related diseases in mammals and especially in man, including e.g. reflux oesophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer. Furthermore, they may be used for treatment of other gastrointestinal disorders where gastric acid inhibitory effect is desirable e.g. in patients on NSAID therapy, in patients with Non Ulcer Dyspepsia, in patients with symptomatic gastro oesophageal reflux disease, and in patients with gastrinomas. They may also be used in patients in intensive care situations, in patients with acute upper gastrointestinal bleeding, pre- and postoperatively to prevent aspiration of gastric acid and to prevent and treat stress ulceration. Further, they may be useful in the treatment of psoriasis as well as in the treatment of Helicobacter infections and diseases related to these.
The active compounds are, however, susceptible to degradation/transformation in acidic reacting and neutral media. The degradation is catalyzed by acidic reacting compounds. The active compounds are stabilized with alkaline reacting compounds. Thus, the active substance being a proton pump inhibitor is best protected by an enteric coating layer. There are different enteric coating layered preparations of omeprazole as well as other proton pump inhibitors described in the prior art, see for example U.S. Pat. No. 4,786,505 (AB Hassle).
There has been a demand for a formulation with a rapid dissolution and a quick onset of action, furthermore a formulation which is pleasant to take for the patient and also which is suitable for patients with swallowing difficulties (dysphagia). There are a number of dosage forms that hold a good deal of promise in administering proton pump inhibitors. However, it has been difficult to find a vehicle which can satisfy all of many and some times conflicting needs and desires for such a dosage form.
One possible vehicle for administration of these active agents is effervescent tablets. Effervescence provides generally some measure of taste-masking. Prior to being taken by the patient, an effervescent composition is dissolved and/or dispersed in for example an aqueous medium, such as drinking water. Dissolution and/or dispersion takes place rapidly, with effervescence to give an agreeable presentation of the drug, particularly for patients who do not like tablets or find difficulty in swallowing tablets.
Effervescent compositions usually contain, in addition to the active ingredient, a source of carbon dioxide (such as an alkaline carbonate or bicarbonate) and an acid (such as for instance citric acid). The use of an acid in effervescent compositions in which the active ingredient is an acid labile substance such as an acid susceptible proton pump inhibitor presents a problem due to the instability of the proton pump inhibitor in the presence of acid.
Replacement of citric acid by monosodium citrate still fails to give a satisfactory level of stability of an acid labile histamine H.sub.2 -antagonist, whilst replacement of citric acid by disodium citrate results in insufficient effervescen
REFERENCES:
patent: 4289751 (1981-09-01), Windheuser
patent: 4786505 (1988-11-01), Lovgren et al.
patent: 4853230 (1989-08-01), Lovgren et al.
patent: 5753265 (1998-05-01), Bergstarnd et al.
patent: 5817338 (1998-10-01), Bergstrand et al.
patent: 5824339 (1998-10-01), Shimizu et al.
patent: 5840737 (1998-11-01), Phillips
Lehmann et al. (1994) "Fast disintegrating controlled release tablets from coated particles" Drugs made in Germany 37:53-60.
Wan, L.S.C., "A Multiple-unit Tablet Formulation for Multi-layer Drug-coated Granules", S.T.P. Pharma Sciences, 4(5) (1994), pp. 336-342.
Astrazeneca AB
Spear James M.
LandOfFree
Multiple unit effervescent dosage forms comprising proton pump i does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multiple unit effervescent dosage forms comprising proton pump i, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multiple unit effervescent dosage forms comprising proton pump i will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-465965